The use of Whole-Genome Sequencing has increased the diagnostic yield for rare diseases. However, even WGS fails to identify the genetic cause in about 50% of patients. To increase this yield, the NIHR National BioResource launched the RNA phenotyping initiative which adds RNAseq and proteomic to WGS. The project aims to develop approaches for integrating these data to discover new causes of disease in a unique cohort of a thousand rare disease patients.
The use of Whole-Genome Sequencing has dramatically increased the diagnostic yield and shortened the time to diagnosis for individuals affected by rare diseases. However, WGS still fails to identify the underlying genetic cause in about 50% of patients. This is due to several factors including: (i) lack of statistical power due to small sets of cases with different genetic aetiology, (ii) difficulty in predicting the consequences of a number of causal genetic variants, and lastly, (iii) the current technology used in WGS cannot detect structural variants.
To increase the percentage of individuals receiving a diagnosis the NIHR National BioResource for Rare Diseases launched the RNA phenotyping initiative. Here WGS is supplemented with RNA sequencing from four blood cell types and proteomic data from the same cells and plasma. This unique dataset provides an exciting opportunity to extend genotyping with functional measurements of gene expression at the messenger RNA and protein level. By understanding how gene expression varies with genotype and disease status, this will allow the identification of novel genetic aetiologies. It will enhance our understanding of human biology, improve the diagnostic yield of clinical genetic analyses, improve prognostication, and inform the development of treatments.
The candidate will join a group with an extensive track record of studying blood disorders and they will be part of a multidisciplinary collaborative research environment that includes medics, biologists, statisticians and bioinformaticians. The aim of the project is to develop approaches for integrating and exploiting the novel collected data and apply these to discover new causes of disease in a unique cohort of a thousand rare disease patients, boosting the diagnostic power of genetic testing and broadening access to precision medicine. The candidate will take ownership of guided identification of computational methods, their application, together with method development where necessary to integrate genotype and gene expression data.
To focus the studentship, the candidate will work with data from a selected group of patients presenting with platelet and bleeding disorders akin to storage pool disorder but with a still unresolved genetic cause. The student will have access to data generated using recall by genotype studies. Employing this, they will lead the analyses and with the direction of the supervisory team, will coordinate the assembly of evidence to support the publication of their findings in peer-reviewed journals.
How to apply
Applications open 2nd September and close at 17:00 on 2nd November 2022
To begin a GW4 BioMed MRC DTP studentship, applicants must secure an offer of funding from the DTP.
For full information on the studentship including entry requirements/academic requirements/English language requirements/eligibility and selection criteria please visit - https://www.exeter.ac.uk/study/funding/award/?id=4527